Aldeyra Therapeutics, Inc.ALDX

Market cap

$300.08M

P/E ratio

	2014/12	2015/12	2016/12	2017/12	2018/12	2019/12	2020/12	2021/12	2022/12	2023/12	2024/12
Cash and cash equivalents	9	15	12	20	47	44	78	230	144	143	55
Marketable securities, current	-	13	13	23	92	29	-	-	30	-	47
Total cash & short-term investments	9	28	25	43	140	73	78	230	174	143	101
Total current assets	9	28	25	44	95	75	83	233	181	148	104
Property, plant and equipment, net	12,993	80,334	56,352	43,262	235,225	148,449	59,925	32,487	19,279	5,764	-
Total non-current assets	27,231	116,570	56,352	209,192	321,869	349,456	293,235	384,350	268,544	516,578	534,216
Total assets	9	28	25	44	95	76	83	233	181	148	105
Accounts payable	341,294	851,160	275,441	1	3	808,302	381,638	1	133,625	1	180,453
Long-term debt, current	77,546	77,546	77,546	116,319	-	-	-	-	911,763	15	31,372
Total current liabilities	1	2	2	3	8	13	12	12	15	22	19
Long-term debt, non-current	1	1	1	1	-	15	11	16	15	-	15
Total non-current liabilities	1	1	1	1	-	15	11	16	15	6	15
Total liabilities	3	3	4	5	8	27	24	27	30	29	34
Common stock and paid-in capital	-	9,713	12,576	19,138	26,244	28,657	38,667	58,081	58,560	59,196	59,648
Retained earnings	-46,511,597	-58,601,884	-77,301,334	-99,641,923	-138,535,168	-199,361,999	-236,915,728	-294,692,002	-356,716,638	-394,259,148	-450,110,592
Stockholders' equity	6	25	22	40	87	48	60	206	151	120	71
Total debt	1	1	1	1	-	15	11	16	16	15	15
Net debt	-7,274,277	-26,301,786	-23,596,475	-41,610,288	-	-58,836,163	-66,423,855	-214,287,286	-158,466,031	-127,676,470	-86,119,900
D/E ratio (%)	19.9	5.2	6.1	3.4	-	30.2	19.2	7.5	10.5	12.6	21.2